# US Human Genetics Market > US Human Genetics Market Research Report By Application (Wellness & E-Commerce, Preventive Medicine, Diagnostic & Treatment) and By Test (NIPT, Carrier Testing, Pharmacogenomic Testing, Karyotype Testing, Thrombophilia Testing, Septin 9 Biomarker Testing, NGS, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 10.8% - **2024:** $ 8.9 Billion - **2025:** $ 9.86 Billion - **2035:** $ 27.51 Billion - **Key Players:** Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Agilent Technologies (US), QIAGEN (DE), Myriad Genetics (US), BGI Genomics (CN), Genomatix (DE), Invitae (US) **Report ID:** MRFR/LS/11818-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-human-genetics-market-13343 --- ## Market Summary ## **US Human Genetics Market Overview** As per MRFR analysis, the US Human Genetics Market Size was estimated at 4.59 (USD Billion) in 2023. The US Human Genetics Market Industry is expected to grow from 5.5(USD Billion) in 2024 to 17.5 (USD Billion) by 2035. The US Human Genetics Market CAGR (growth rate) is expected to be around 11.096% during the forecast period (2025 - 2035). ### **Key US Human Genetics Market Trends Highlighted** The US [Human Genetics](../../../reports/human-genetics-market-714) Market is experiencing significant trends driven by advancements in technology, increasing awareness regarding genetic disorders, and a growing emphasis on personalized medicine. As genomic sequencing becomes more accessible and affordable, healthcare providers are increasingly integrating genetic testing into clinical practices. This integration is supported by the rise in demand for early diagnosis, which is crucial for managing inherited diseases. Additionally, the US government is enhancing funding and support for genomics research, reflecting its role in modern healthcare. Opportunities in the market are expanding as institutions focus on developing innovative therapies and precision medicine tailored to individual genetic profiles. The establishment of partnerships between biotech firms and academic institutions is fostering research and development, particularly in areas like gene therapy and CRISPR technology. This collaboration can potentially accelerate product development and bring new solutions to the market. Recent trends include an increased focus on population genomics, which allows researchers to identify genetic variations within diverse communities, thus improving health outcomes on a broader scale. Moreover, legislative efforts are being made to address ethical considerations related to genetic data use and privacy, which is a critical factor in gaining public trust. As consumer interest in health and genetics grows, the market is likely to see a rise in direct-to-consumer genetic testing services, leading to more informed healthcare decisions among individuals. Overall, the US Human Genetics Market is evolving rapidly, driven by technological advancements and the quest for personalized healthcare solutions. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Human Genetics Market Drivers** ### **Rising Incidence of Genetic Disorders** The US Human Genetics Market Industry is experiencing significant growth due to the increasing incidence of genetic disorders. According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 33 infants is born with a genetic disorder in the United States, amounting to nearly 120,000 affected infants each year. This alarming statistic underscores the urgent need for genetic testing and therapies, thereby propelling advancements in genetic research and diagnostics. Leading organizations such as the National Institutes of Health (NIH) are heavily invested in genetic research, working towards understanding and eventually treating these disorders. Additionally, the advocacy of groups like the Genetic Alliance has further mobilized awareness and funding for genetic conditions, creating an environment ripe for innovation and growth within the US Human Genetics Market. Furthermore, with technological advancements in genome sequencing becoming more affordable and accessible, the demand for genetic tests is expected to increase, driving the market upwards. ### **Integration of Genetic Technology in Healthcare** The integration of genetic technology into the healthcare system is significantly driving the US Human Genetics Market Industry. Hospitals and healthcare providers are increasingly adopting precision medicine, which utilizes genetic data to personalize treatment plans for patients. The American Medical Association has noted a 35% increase in the adoption of genetic testing among healthcare providers over the last three years. This trend is supported by organizations such as the Mayo Clinic, which is pioneering the use of genetic information in clinical decision-making. As more healthcare providers integrate genetic testing into routine care, the demand for genetic services is expected to surge, further fueling market growth. ### **Increased Funding for Genetic Research** Funding for genetic research in the United States has seen a substantial rise, acting as a significant driver for the US Human Genetics Market Industry. The NIH reported an 11% increase in its funding for genomics research in the previous fiscal year, totaling over 13 billion USD dedicated to various genetic studies. This influx of funding facilitates Research and Development (R&D) of new genetic therapies and technologies, making clinical applications more advanced and effective. Organizations like the Howard Hughes Medical Institute are also adding to this momentum by supporting innovative genetic research projects that pave the way for breakthroughs in the field. ## **US Human Genetics Market Segment Insights** ### **Human Genetics Market Application Insights** The Application segment of the US Human Genetics Market holds a significant role in driving the industry's growth, reflecting an evolving landscape primarily shaped by advancements in genetics and personalized medicine. With the overall market expected to witness substantial growth in the coming years, various applications within this segment are making profound impacts on healthcare initiatives and consumer behavior. Wellness and E-Commerce have become increasingly intertwined, as personalized genetic testing becomes a prominent tool for consumers seeking actionable insights into their health. This growing trend has enabled the emergence of an informed consumer base eager to engage in proactive health management, thereby enhancing the demand for genetic testing services that cater to wellness-oriented consumers. In the field of Preventive Medicine, the ability to identify genetic predispositions to certain health conditions positions genetic testing as a crucial component in healthcare strategies designed to mitigate risks and promote early intervention. By understanding genetic factors, medical professionals can create tailored preventive care plans for patients, ultimately increasing their engagement in health management activities and, consequently, improving health outcomes. This emphasis on preventive measures is not only aligning with the broader healthcare goals of reducing costs associated with chronic diseases but also reshaping the responsibilities placed on both patients and healthcare providers in the United States. Moreover, the Diagnostic and Treatment subfield represents a key growth area within the Application segment, leveraging genetic information to refine diagnosis and pave the way for targeted therapies. By integrating genetic insights into clinical practices, healthcare practitioners can enhance diagnostic accuracy, leading to improved treatment protocols tailored to individual patient profiles. This targeted approach is increasingly recognized as a vital method for addressing complex health issues, particularly in oncology and rare genetic disorders, where traditional therapeutic strategies may not be as effective. As discussions around ethical, legal, and social implications of genetic testing become increasingly prominent, the US Human Genetics Market must address these challenges to foster further acceptance and utilization of genetic services. Legislative developments and policy initiatives focused on genetic privacy and equity in access to care are likely to shape the market landscape, ensuring that advancements in genetics benefit a broader population. The intersection of technology, consumer expectations, and healthcare realities fuels ongoing investment in the Application segment, indicating a robust future for the US Human Genetics Market as it continues to develop in these dynamic and complex landscapes. As a result, the growing application of genetics across various health-focused initiatives underscores the potential to revolutionize how healthcare is delivered, personalized, and optimized for diverse populations. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Human Genetics Market Test Insights** The US Human Genetics Market segment for Tests plays a pivotal role in the overall healthcare landscape, reflecting advancements in genetic technologies that drive both innovation and demand. Non-invasive prenatal testing (NIPT) stands out as particularly significant due to its ability to detect fetal anomalies early, promoting safer prenatal care. Carrier Testing has become essential for individuals and families planning for children, enabling them to make informed decisions regarding genetic disorders. Pharmacogenomic Testing is increasingly crucial, as it personalizes medication plans based on an individual’s genetic makeup, thus improving therapeutic outcomes and minimizing adverse effects. Karyotype Testing offers valuable insights into chromosomal abnormalities, aiding in the diagnosis of various genetic conditions. Thrombophilia Testing assesses the risk of blood clotting disorders, which is vital for patient management and preventive care. The Septin 9 Biomarker Testing is gaining traction in colorectal cancer screenings, providing a non-invasive approach to early detection. Next-generation sequencing (NGS) technologies are revolutionizing the field by facilitating comprehensive genetic analyses and enabling precise genetic research. Each of these segments contributes to the expansive landscape of the US Human Genetics Market, which showcases a strong growth trajectory fueled by increasing awareness, technological advancements, and rising incidences of genetic disorders. ## **US Human Genetics Market Key Players and Competitive Insights** The US Human Genetics Market is characterized by rapid advancements in genetic research and technology, leading to a highly competitive landscape. With the growing demand for personalized medicine, genetic testing, and clinical diagnostics, numerous companies are vying for a prominent position in this sector. The market gets further intensified by continuous innovation, strategic collaborations, and the rise of startups specializing in different aspects of genetic solutions, including oncology, reproductive health, and rare diseases. An increase in awareness about genetic disorders and the potential for targeted therapies has spurred growth in this market, giving rise to new entrants and established organizations striving to enhance their market share and influence. ### **Focusing on Genomic Health** Focusing on Genomic Health, the company has established a strong foothold within the US Human Genetics Market primarily due to its innovative approach in cancer genetics. The strength of Genomic Health lies in its extensive portfolio of molecular diagnostics, specifically tailored for oncology, which enables healthcare providers to make informed treatment decisions. By pioneering next-generation sequencing technologies and offering tests that are crucial for personalized therapy, the company has positioned itself as a leader in the market. The focus on accuracy, speed in testing, and the development of predictive models has fortified its competitive edge, making Genomic Health a favored choice among clinicians and patients in the US. ### **Myriad Genetics** Myriad Genetics has also carved a significant niche within the US Human Genetics Market through its provision of various genetic testing services that focus on women's health and hereditary cancer. Their key offerings include risk assessment tests like BRCA and hereditary cancer tests, which cater to patients undergoing genetic evaluation for cancer predisposition. The strength of Myriad Genetics lies in its groundbreaking tests that facilitate preventive strategies and personalized treatment plans. The company's robust market presence is also bolstered through strategic mergers and acquisitions, allowing it to expand its capabilities and product range effectively. Additionally, Myriad Genetics invests significantly in research and development, ensuring it remains at the forefront of genetic testing innovation. Their commitment to improving patient outcomes through accessible and reliable genetic testing further enhances their stronghold in the US market. ### **Key Companies in the US Human Genetics Market Include** ## **US Human Genetics Market Industry Developments** The US Human Genetics Market has seen significant developments recently, driven by advancements in genomic technologies and increasing demand for personalized medicine. Notable players such as Genomic Health and Myriad Genetics are expanding their product portfolios, particularly in hereditary cancer testing and precision medicine solutions. Bristol-Myers Squibb and Pfizer have been focusing on Research and Development to incorporate genetic insights into drug discovery, enhancing the efficacy of treatments. In terms of mergers and acquisitions, Rocket Pharmaceuticals announced its acquisition of a gene therapy company in September 2023, broadening its therapeutic pipeline. Illumina continues to consolidate its position in the market, while Veracyte secured partnerships to enhance its diagnostics capabilities by integrating genomic data analysis in July 2023. Recent growth in the market valuations of these companies has also shaped investor confidence, with Thermo Fisher Scientific and GSK reporting substantial increases in stock performance due to their targeted genetic research initiatives. Major events in the past two years, such as the unification of regulatory standards for genetic testing in December 2022, have positively influenced innovation and investment in the US Human Genetics Market. ## **US Human Genetics Market Segmentation Insights** ### **Human Genetics Market Application Outlook** ### **Human Genetics Market Test Outlook** - NIPT - Carrier Testing - Pharmacogenomic Testing - Karyotype Testing - Thrombophilia Testing - Septin 9 Biomarker Testing - NGS - Others ## Market Drivers ### Expansion of Genetic Testing Services The expansion of genetic testing services is a key driver of growth in the human genetics market. With the increasing availability of direct-to-consumer genetic tests and the integration of genetic testing into routine healthcare, more individuals are opting for genetic assessments. This trend is supported by advancements in technology that allow for rapid and cost-effective testing. As of 2025, the market for genetic testing services is projected to exceed $10 billion, driven by demand for carrier screening, prenatal testing, and hereditary cancer testing. Furthermore, healthcare providers are recognizing the value of genetic testing in guiding treatment decisions and improving patient outcomes, which is likely to further stimulate the human genetics market. ### Growing Awareness of Genetic Disorders There is a rising awareness of genetic disorders among the general population, which is contributing to the expansion of the human genetics market. Educational initiatives and advocacy groups are playing a crucial role in informing individuals about the implications of genetic conditions and the importance of genetic testing. As awareness increases, more individuals are seeking genetic counseling and testing services, leading to a higher demand for genetic diagnostics. In the US, it is estimated that approximately 1 in 4 individuals may be affected by a genetic disorder, underscoring the need for effective screening and management strategies. This heightened awareness is likely to drive investments in genetic research and testing services, further propelling the human genetics market. ### Regulatory Support for Genetic Research Regulatory frameworks in the US are increasingly supportive of genetic research, which is fostering growth in the human genetics market. Government agencies, such as the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), are providing funding and guidance for genetic studies and clinical trials. This support is crucial for the development of innovative genetic therapies and diagnostic tools. As of 2025, federal funding for genetic research has reached approximately $3 billion annually, reflecting a commitment to advancing the field. Additionally, streamlined regulatory processes for genetic testing and therapies are likely to encourage more companies to enter the market, thereby enhancing competition and innovation within the human genetics sector. ### Increasing Demand for Personalized Medicine The human genetics market is experiencing a notable surge in demand for personalized medicine, driven by advancements in genetic research and technology. Patients increasingly seek tailored treatment options based on their genetic profiles, which can lead to more effective therapies and improved health outcomes. According to recent estimates, the personalized medicine sector is projected to reach approximately $2 trillion by 2025, indicating a robust growth trajectory. This trend is likely to propel the human genetics market as healthcare providers and pharmaceutical companies invest in genetic testing and analysis to develop customized treatment plans. Furthermore, the integration of genetic insights into clinical practice is expected to enhance patient engagement and adherence to treatment protocols, thereby fostering a more patient-centric approach in the healthcare landscape. ### Technological Advancements in Genetic Sequencing Technological innovations in genetic sequencing are significantly impacting the human genetics market. The advent of next-generation sequencing (NGS) technologies has drastically reduced the cost and time required for genetic analysis, making it more accessible to both researchers and clinicians. As of 2025, the cost of sequencing a human genome has decreased to around $1,000, facilitating widespread adoption in clinical settings. This democratization of genetic testing is likely to drive growth in the human genetics market, as healthcare providers increasingly utilize these technologies for diagnostics, disease prevention, and treatment planning. Moreover, advancements in bioinformatics tools are enhancing the ability to interpret complex genetic data, further supporting the integration of genetic information into routine healthcare practices. ## Future Outlook The [Human Genetics Market](https://www.marketresearchfuture.com/reports/human-genetics-market-714) is projected to grow at a 10.8% CAGR from 2025 to 2035, driven by advancements in genomic technologies, personalized medicine, and increasing healthcare investments. **New opportunities:** - Development of AI-driven genetic analysis platforms - Expansion of direct-to-consumer genetic testing services - Partnerships with biotech firms for innovative gene therapies By 2035, the human genetics market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Application: Wellness & E-Commerce (Largest) vs. Preventive Medicine (Fastest-Growing) In the US human genetics market, Wellness & E-Commerce holds a substantial share, driven by increased consumer awareness regarding genetic health and the availability of personalized wellness solutions. This segment's dominance can be attributed to the growing demand for at-home genetic testing kits, which provide insights into health, ancestry, and lifestyle choices. Conversely, Preventive Medicine is rapidly gaining traction, reflecting a shift towards proactive health management strategies aimed at early detection and prevention of diseases. The growth of the Preventive Medicine segment is fueled by technological advancements in genetic testing and an increasing focus on personalized medicine. As healthcare providers emphasize preventative care, the market for genetic testing in early diagnosis is expected to expand significantly. The integration of genetic information into routine health assessments allows for better-targeted treatments and can substantially improve health outcomes, positioning this segment as the fastest-growing area in the market. Wellness & E-Commerce (Dominant) vs. Preventive Medicine (Emerging) The Wellness & E-Commerce segment is characterized by a broad range of offerings, including direct-to-consumer genetic tests that cater to health, fitness, and ancestry. This segment has thrived due to the convenience of online purchasing and the growing popularity of personalized health insights among consumers. The availability of various platforms for genetic testing allows customers access to a wealth of information about their genetic predispositions, attracting a diverse demographic. On the other hand, Preventive Medicine presents an emerging opportunity within the US human genetics market, emphasizing the role of genetic testing in identifying risk factors for diseases before they manifest. With healthcare policies increasingly advocating for prevention, this segment is likely to see unprecedented growth as more individuals seek genetic testing services to inform their healthcare decisions. Collaborative efforts between genetic testing companies and healthcare providers will further enhance its effectiveness and reach. ### By Test: NIPT (Largest) vs. Carrier Testing (Fastest-Growing) In the US human genetics market, Non-Invasive Prenatal Testing (NIPT) holds the largest market share among various testing methods, dominating choice for early genetic screening due to its accuracy and non-invasive nature. Carrier Testing follows as a significant segment, offering insights into genetic conditions that can be passed to offspring, thereby capturing the attention of prospective parents and healthcare providers. The growth trends indicate a notable rise in Carrier Testing, spurred by increasing awareness and a heightened emphasis on individualized medicine. The demand for personalized genetic insights continues to drive the adoption of pharmacogenomic, Karyotype, and Thrombophilia Testing. Innovations in Next-Generation Sequencing (NGS) technology further enhance testing capabilities, positioning these segments for expansive growth in the foreseeable future. NIPT (Dominant) vs. Carrier Testing (Emerging) NIPT has become the dominant choice for prenatal genetic screening, thanks to its accuracy and minimal risk, rendering it a preferred option for expectant mothers. Its non-invasive approach not only ensures safety for both mother and fetus but also delivers timely insights into potential genetic anomalies. On the other hand, Carrier Testing is emerging rapidly, supported by a growing trend towards personalized medicine, enabling couples to make informed reproductive choices. As healthcare providers advocate for preconception genetic counseling, the demand for Carrier Testing is expected to escalate. The technological advancements in genetic testing methodologies continue to shape the competitive landscape, making these segments crucial for stakeholders in the US human genetics market. ## Competitive Benchmarking The human genetics market is characterized by a dynamic competitive landscape, driven by advancements in technology, increasing demand for personalized medicine, and a growing emphasis on genetic research. Key players such as Illumina (US), Thermo Fisher Scientific (US), and Myriad Genetics (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Illumina (US) focuses on next-generation sequencing technologies, while Thermo Fisher Scientific (US) emphasizes a broad portfolio of genetic analysis tools. Myriad Genetics (US) is increasingly investing in precision medicine, particularly in oncology, which collectively shapes a competitive environment that is both innovative and rapidly evolving.The market structure appears moderately fragmented, with several players vying for market share through various business tactics. Companies are localizing manufacturing to reduce costs and optimize supply chains, which enhances their operational efficiency. The collective influence of these key players fosters a competitive atmosphere where collaboration and innovation are paramount, allowing for a diverse range of products and services that cater to the evolving needs of healthcare providers and researchers. In October Illumina (US) announced a strategic partnership with a leading pharmaceutical company to develop genomic-based therapies. This collaboration is expected to accelerate the integration of genomic data into drug development processes, potentially revolutionizing treatment protocols and enhancing patient outcomes. Such strategic moves indicate a shift towards more personalized healthcare solutions, aligning with broader industry trends. In September Myriad Genetics (US) launched a new genetic testing service aimed at identifying hereditary cancer risks. This service not only expands their product offerings but also positions the company as a leader in the precision medicine space. The introduction of this service reflects a growing trend towards proactive healthcare measures, emphasizing the importance of genetic insights in disease prevention and management. In August Thermo Fisher Scientific (US) unveiled a new line of CRISPR-based gene editing tools, aimed at enhancing research capabilities in genetic engineering. This innovation is likely to strengthen their competitive edge by providing researchers with advanced tools that facilitate groundbreaking studies in genetics. The emphasis on cutting-edge technology underscores the importance of continuous innovation in maintaining market leadership. As of November current competitive trends in the human genetics market include a pronounced focus on digitalization, sustainability, and the integration of artificial intelligence (AI) into genetic research and diagnostics. Strategic alliances are increasingly shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition towards a focus on technological advancements, innovation, and supply chain reliability. This transition suggests that companies that prioritize these elements will likely emerge as leaders in the market. ## Recent News & Developments The US Human Genetics Market has seen significant developments recently, driven by advancements in genomic technologies and increasing demand for personalized medicine. Notable players such as Genomic Health and Myriad Genetics are expanding their product portfolios, particularly in hereditary cancer testing and precision medicine solutions. Bristol-Myers Squibb and Pfizer have been focusing on Research and Development to incorporate genetic insights into drug discovery, enhancing the efficacy of treatments. In terms of mergers and acquisitions, Rocket Pharmaceuticals announced its acquisition of a gene therapy company in September 2023, broadening its therapeutic pipeline. Illumina continues to consolidate its position in the market, while Veracyte secured partnerships to enhance its diagnostics capabilities by integrating genomic data analysis in July 2023. Recent growth in the market valuations of these companies has also shaped investor confidence, with Thermo Fisher Scientific and GSK reporting substantial increases in stock performance due to their targeted genetic research initiatives. Major events in the past two years, such as the unification of regulatory standards for genetic testing in December 2022, have positively influenced innovation and investment in the US Human Genetics Market. ## Report Scope | MARKET SIZE 2024 | 8.9(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 9.86(USD Billion) | | MARKET SIZE 2035 | 27.51(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.8% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Roche (CH), Agilent Technologies (US), QIAGEN (DE), Myriad Genetics (US), BGI Genomics (CN), Genomatix (DE), Invitae (US) | | Segments Covered | Application, Test | | Key Market Opportunities | Advancements in gene editing technologies create transformative opportunities in the human genetics market. | | Key Market Dynamics | Technological advancements drive innovation in genetic testing, enhancing personalized medicine and consumer demand in the human genetics market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US human genetics market in 2024?** A: The market valuation of the US human genetics market was $8.9 Billion in 2024. **Q: What is the projected market valuation for the US human genetics market by 2035?** A: The projected market valuation for the US human genetics market is $27.51 Billion by 2035. **Q: What is the expected CAGR for the US human genetics market during the forecast period 2025 - 2035?** A: The expected CAGR for the US human genetics market during the forecast period 2025 - 2035 is 10.8%. **Q: Which segments are expected to drive growth in the US human genetics market?** A: Segments such as Wellness & E-Commerce, Preventive Medicine, and Diagnostic & Treatment are expected to drive growth. **Q: What was the valuation of the Wellness & E-Commerce segment in 2024?** A: The valuation of the Wellness & E-Commerce segment was $3.56 Billion in 2024. **Q: How much is the NIPT segment projected to be worth by 2035?** A: The NIPT segment is projected to be worth $4.5 Billion by 2035. **Q: Which companies are considered key players in the US human genetics market?** A: Key players in the US human genetics market include Illumina, Thermo Fisher Scientific, and Myriad Genetics. **Q: What was the market size for Diagnostic & Treatment in 2024?** A: The market size for Diagnostic & Treatment was $2.67 Billion in 2024. **Q: What is the projected growth for Carrier Testing by 2035?** A: Carrier Testing is projected to grow to $3.6 Billion by 2035. **Q: How does the projected market growth for 2035 compare to 2024?** A: The projected market growth for 2035 indicates a substantial increase from the $8.9 Billion valuation in 2024. **Q: What is the projected market size of the US Human Genetics Market in 2024?** A: The US Human Genetics Market is expected to be valued at 5.5 billion USD in 2024. **Q: What is the expected market size of the US Human Genetics Market by 2035?** A: By 2035, the US Human Genetics Market is projected to reach a value of 17.5 billion USD. **Q: What is the expected compound annual growth rate (CAGR) for the US Human Genetics Market from 2025 to 2035?** A: The market is expected to grow at a CAGR of 11.096% during the period from 2025 to 2035. **Q: Which application segment is expected to have the largest market size in the US Human Genetics Market by 2035?** A: Wellness & E-Commerce is expected to be the largest application segment, valued at 5.0 billion USD by 2035. **Q: What is the projected market size of the Preventive Medicine segment in 2035?** A: The Preventive Medicine segment is anticipated to reach a market size of 6.5 billion USD by 2035. **Q: Which companies are considered major players in the US Human Genetics Market?** A: Key players in the market include Illumina, Roche Diagnostics, Myriad Genetics, and Thermo Fisher Scientific. **Q: What is the market size for the Diagnostic & Treatment segment in 2024?** A: The Diagnostic & Treatment segment is expected to be valued at 2.0 billion USD in 2024. **Q: What opportunities exist for growth in the US Human Genetics Market?** A: Emerging trends in personalized medicine and advancements in genetic testing present significant growth opportunities. **Q: How does the US Human Genetics Market contribute to preventive medicine?** A: The market's growth in preventive medicine indicates an increasing focus on early detection and risk assessment through genetic testing. **Q: What future trends could impact the US Human Genetics Market?** A: Trends such as increased consumer awareness and integration of genetics into routine healthcare are likely to drive market growth. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-human-genetics-market-13343*